Judge Voids Appointments to US Vaccine Panel

A federal court ruling has thrown the United States’ vaccine advisory process into uncertainty by nullifying the appointments of 13 members of the Advisory Committee on Immunization Practices (ACIP). The decision, issued on September 18, 2025, in Chamblee, Georgia, leaves the country without a fully functioning federal panel that typically underpins official vaccine guidance.

The immediate practical effect is procedural rather than clinical: vaccines such as the latest seasonal influenza and updated COVID-19 shots remain available, but the formal recommendations that usually accompany annually revised products are now in question. The ruling also places pending decisions—such as whether an RSV vaccine for infants should be included in the federal Vaccines for Children program—into a holding pattern.

What changed, and why it matters now

The 13 members whose appointments were invalidated had been selected by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. after he removed 17 prior ACIP members in June. The judge found the new appointees were not properly chosen and described them as unqualified, effectively wiping out the reconstituted committee.

ACIP recommendations are a key link in how the U.S. government signals which vaccines should be used, for whom, and on what schedule. When that link is disrupted, downstream decisions by providers, insurers, and state-level systems can become harder to standardize, particularly for products that are updated each year.

Operational and legal knock-on effects

One near-term risk flagged in the public discussion is provider hesitation in certain jurisdictions. In some states, pharmacists’ willingness to administer particular vaccines can be influenced by liability protections under the Prep Act, which are tied to endorsements connected to the CDC and ACIP.

That creates a potential gap between vaccine availability and vaccine delivery, even if supply is unchanged. The extent of any disruption is uncertain and likely to vary by state rules and how strictly providers interpret the relationship between federal recommendations and liability coverage.

Institutional responses and leadership uncertainty

The American Academy of Pediatrics (AAP) said it would challenge any committee that is not formed through what it considers proper procedures. Separately, former ACIP co-chair Robert Malone said he has been pushed out and will not take part in future decisions, attributing his departure to “drama” and “sabotage.”

An HHS spokesperson, Andrew Nixon, rejected claims that ACIP had been disbanded and said official announcements would come from the department. HHS is reported to be planning new appointments, a process estimated to require four to six months.

Broader context for markets and policy

The ruling lands amid leadership churn at the Centers for Disease Control and Prevention (CDC), where the agency has had four acting directors over the past year. Donald Trump is expected to name a new CDC director soon, adding another moving part to the federal public-health governance picture.

For markets, the key issue is not vaccine supply but policy clarity: ACIP guidance can influence coverage decisions and provider behavior, which in turn can affect demand patterns for seasonal and updated vaccines. Until a legally constituted panel is in place, the timeline for formal recommendations—and the consistency of vaccine delivery across states—remains an open question.